• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Ripalid
    / Perrigo


    Active Ingredient
    Repaglinide 0.5, 1, 2 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    90 X 0.5 mg

    not in the basket chart 63286

    Tablets

    90 X 1 mg

    not in the basket chart 63287

    Tablets

    90 X 2 mg

    not in the basket chart 63288

    Related information


    Dosage

    Usually initial dose is 0.5 mg, 30 min. before each main meal, with a glass of water. Dose may be increased up to 16 mg a day according to patient needs.
    Please refer to the license holder for further details.


    Indications

    Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
    Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.
    Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.  


    Contra-Indications

    Hypersensitivity to Active Substance or any of Its Excipients. Patients wth type 1 diabetes. Patients with diabetic ketoacidosis. Severe liver disease. Concomitant use with gemfibrozil.


    Manufacturer
    Rivopharm SA
    CLOSE